18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma - PubMed (original) (raw)
18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma
Jun Sato et al. J Nucl Med. 2013 Jul.
Free article
Abstract
Hypoxia is a common feature of cancer and a prognostic factor for many types of cancer. (18)F-fluoromisonidazole ((18)F-FMISO) PET can detect tumor hypoxia noninvasively. Hypoxia-inducible factor-1 (HIF-1) is a key player in the transcriptional response to low oxygen tension in many types of cancer. Its activity is mainly dependent on the stability and modification of HIF-1α, which is a composition of HIF-1. However, it is unclear whether (18)F-FMISO PET can identify HIF-1α expression in oral squamous cell carcinoma (OSCC). The present study was performed to elucidate the correlation between (18)F-FMISO PET findings and HIF-1α expression in OSCC.
Methods: Twenty-three patients (age range, 42-84 y; 15 men, 8 women) with OSCC were enrolled in this study. The T-stages of cancer were T1 in 1 patient, T2 in 9, T3 in 2, and T4a in 11. The N-stages were N0 in 13 patients, N1 in 5, and N2 in 5. Each patient underwent (18)F-FMISO and (18)F-FDG PET before surgery, and the maximum standardized uptake value (SUV max) of both PET studies was measured. HIF-1α expression in the operation materials was evaluated by immunohistochemical staining. The SUV max of both PET studies and HIF-1α findings were compared statistically.
Results: (18)F-FMISO PET detected uptake in the primary site in 14 of the 23 patients (61%). The median SUV max of (18)F-FMISO and (18)F-FDG PET in the primary site was 1.83 (range, 0.8-2.7) and 16.5 (range, 1.0-32.3), respectively. There was a weak significant correlation between (18)F-FMISO and (18)F-FDG PET SUV max (P = 0.02, r = 0.48). HIF-1α expression was clearly detected in 11 of the 23 patients (48%). The (18)F-FMISO PET SUV max was significantly higher in the HIF-1α-positive cases than in the HIF-1α-negative cases (median, 2.1; range, 1.5-2.4, vs. median, 1.6; range, 0.8-2.0, respectively) (P = 0.002). However, there were no significant correlations between (18)F-FDG PET SUV max and HIF-1α expression (median, 21.8; range, 7.7-29.1 vs. 1.0-32.2) (P = 0.06).
Conclusion: (18)F-FMISO uptake in the primary site of OSCC indicates a hypoxic environment with HIF-1α expression.
Keywords: FMISO PET; HIF-1α; hypoxia; oral squamous cell carcinoma.
Similar articles
- Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma.
Sato J, Kitagawa Y, Yamazaki Y, Hata H, Asaka T, Miyakoshi M, Okamoto S, Shiga T, Shindoh M, Kuge Y, Tamaki N. Sato J, et al. Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2031-41. doi: 10.1007/s00259-014-2810-y. Epub 2014 May 28. Eur J Nucl Med Mol Imaging. 2014. PMID: 24867258 - 18F-Fluoromisonidazole positron emission tomography (FMISO-PET) may reflect hypoxia and cell proliferation activity in oral squamous cell carcinoma.
Sato J, Kitagawa Y, Watanabe S, Asaka T, Ohga N, Hirata K, Okamoto S, Shiga T, Shindoh M, Kuge Y, Tamaki N. Sato J, et al. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Sep;124(3):261-270. doi: 10.1016/j.oooo.2017.05.506. Epub 2017 Jun 8. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017. PMID: 28734696 - Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT.
Wang H, Zhang Y, Yu W, Zhao X, Xue Y, Xu H. Wang H, et al. Nucl Med Commun. 2016 Jul;37(7):705-14. doi: 10.1097/MNM.0000000000000498. Nucl Med Commun. 2016. PMID: 26963468 - FMISO as a Biomarker for Clinical Radiation Oncology.
Zschaeck S, Steinbach J, Troost EG. Zschaeck S, et al. Recent Results Cancer Res. 2016;198:189-201. doi: 10.1007/978-3-662-49651-0_10. Recent Results Cancer Res. 2016. PMID: 27318688 Review. - Tumor hypoxia: a new PET imaging biomarker in clinical oncology.
Tamaki N, Hirata K. Tamaki N, et al. Int J Clin Oncol. 2016 Aug;21(4):619-625. doi: 10.1007/s10147-015-0920-6. Epub 2015 Nov 14. Int J Clin Oncol. 2016. PMID: 26577447 Review.
Cited by
- Hypoxically cultured cells of oral squamous cell carcinoma increased their glucose metabolic activity under normoxic conditions.
Shinohara Y, Washio J, Kobayashi Y, Abiko Y, Sasaki K, Takahashi N. Shinohara Y, et al. PLoS One. 2021 Oct 22;16(10):e0254966. doi: 10.1371/journal.pone.0254966. eCollection 2021. PLoS One. 2021. PMID: 34679081 Free PMC article. - Noninvasive evaluation of 18F-FDG/18F-FMISO-based Micro PET in monitoring hepatic metastasis of colorectal cancer.
Zhang M, Jiang H, Zhang R, Xu H, Jiang H, Pan W, Li X, Wang Y, Wang S. Zhang M, et al. Sci Rep. 2018 Dec 13;8(1):17832. doi: 10.1038/s41598-018-36238-x. Sci Rep. 2018. PMID: 30546057 Free PMC article. - Radiolabeled probes targeting hypoxia-inducible factor-1-active tumor microenvironments.
Ueda M, Saji H. Ueda M, et al. ScientificWorldJournal. 2014;2014:165461. doi: 10.1155/2014/165461. Epub 2014 Aug 18. ScientificWorldJournal. 2014. PMID: 25215311 Free PMC article. Review. - Molecular mechanisms of hypoxia in cancer.
Challapalli A, Carroll L, Aboagye EO. Challapalli A, et al. Clin Transl Imaging. 2017;5(3):225-253. doi: 10.1007/s40336-017-0231-1. Epub 2017 May 11. Clin Transl Imaging. 2017. PMID: 28596947 Free PMC article. Review. - Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma.
Sato J, Kitagawa Y, Yamazaki Y, Hata H, Asaka T, Miyakoshi M, Okamoto S, Shiga T, Shindoh M, Kuge Y, Tamaki N. Sato J, et al. Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2031-41. doi: 10.1007/s00259-014-2810-y. Epub 2014 May 28. Eur J Nucl Med Mol Imaging. 2014. PMID: 24867258
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical